600079.SH
ST人福
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 17.85
−0.22%Year over year
Reported trailing growth
- Revenue
- -5.1%
- EBITDA
- —
- EBIT
- +28.5%
- EPS
- +37.6%
- Free cash flow
- +141.8%
- Operating cash flow
- +56.3%
Forward estimates
Based on analyst estimates
- Revenue
- -48.5%
- EBITDA
- -50.1%
- EPS
- -52.0%
Three-year CAGR
- Revenue
- +2.4%
- EBITDA
- -0.3%
- EBIT
- -3.1%
- Net income
- -9.3%
- EPS
- -9.5%
- Free cash flow
- +1314.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026